Background: Oxametacin is a non-steroidal anti-inflammatory drug with pharmacophores
of classic histone deacetylase inhibitors. To evaluate the histone deacetylase enzymatic
inhibition and antitumor potential of Oxametacin, molecular docking, molecular dynamic
simulation and in vitro activity assay processes were performed in the present study.
Methods: In the docking study, multiple π - π stacking and H-bond interactions were discovered to
play significant roles in the Oxametacin-HDAC3 bindings.
Results: Such interactions were proved to be stable by the molecular dynamic simulation.
Enzymatic inhibition assay showed potent inhibitory activity of Oxametacin (IC50 value of
0.18 µM) against Hela cell nucleus extract compared with SAHA (0.21 µM).
Conclusion: In the isoform selectivity assay, Oxametacin exhibited selectivity for HDAC3
(0.13 µM) over HDAC6 (0.46 µM). In the antiproliferative test, Oxametacin exhibited leukemic
cell lines selectivity against the solid tumor cell lines. Current studies reveal that Oxametacin can be
used as a lead compound in further development of histone deacetylase inhibitors for the anticancer